Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement of its Treg Cell Therapy Pipeline into Clinical Development
August 15, 2024 07:00 ET
|
Abata
Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement of its Treg Cell Therapy Pipeline
Medsenic reçoit l'intention de délivrer un brevet européen clé de l'OEB, précieux pour le développement thérapeutique du trioxyde d'arsenic dans la sclérose en plaques récurrente-rémittente.
August 14, 2024 01:00 ET
|
BioSenic
INFORMATION PRIVILEGIEE Le médicament de Medsenic, le trioxyde d'arsenic, peut maintenant être étudié pour le traitement de la sclérose en plaques par des cycles répétés d'administration par de...
Medsenic receives the intention to grant a key European patent from EPO, valuable for the therapeutic development of arsenic trioxide in relapsing-remitting multiple sclerosis
August 14, 2024 01:00 ET
|
BioSenic
INSIDE INFORMATION Medsenic's experimental drug, arsenic trioxide, can now be investigated for the treatment of multiple sclerosis through repeated cycles of administration by multiple routes,...
Tiziana Life Sciences Granted FDA Fast Track Designation
July 24, 2024 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Abata Therapeutics Announces FDA Clearance of Investigational New Drug Application for Clinical Evaluation of ABA-101 in Progressive Multiple Sclerosis
July 09, 2024 06:00 ET
|
Abata
Abata Therapeutics Announces FDA Clearance of Investigational New Drug Application for Clinical Evaluation of ABA-101 in Progressive Multiple Sclerosis
Courage in the Ring: MS Patient Fights for a Cure
July 08, 2024 09:00 ET
|
London Health Sciences Foundation
An MS patient battles for a cure in a boxing fundraiser aimed at raising funds for the MS Clinic in London, Ontario.
Tiziana Receives $3.4 Million in Non-Dilutive Funding
June 28, 2024 11:01 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough therapies in neurodegenerative...
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
June 11, 2024 08:45 ET
|
FN Media Group LLC
PALM BEACH, Fla., June 11, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - In the last twenty years, the amount of people with multiple sclerosis (MS) in the United States has more than...
FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis
June 11, 2024 08:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, June 11, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Tiziana Life Sciences Announces Six-Month Qualitative Improvement in Neuroimaging in 80% of Multiple Sclerosis Patients Receiving Intranasal Foralumab
June 06, 2024 09:00 ET
|
Tiziana Life Sciences Ltd.
Qualitative improvements in PET imaging seen in 80% of non-active Secondary Progressive Multiple Sclerosis (na-SPMS) Expanded Access patients receiving intranasal foralumab for at least 6-months.FDA...